NuView Radiopharmaceuticals of Park City, UT, has entered an agreement with Thomas Jefferson University to distribute and commercialize a tumor-specific imaging agent used in the diagnosis of breast and prostate tumors.
NuView also intends to sponsor research at Jefferson to further develop the technology. The PET molecular imaging is expected to improve early diagnosis, staging, and monitoring of therapeutic activities for metastatic or recurrent lesions for breast and prostate cancer.
Copyright © 2008 AuntMinnie.com
